



ACQUIRED CARDIOVASCULAR DISEASEIs transapical aortic valve implantation really less invasive than
minimally invasive aortic valve replacement?
Andreas Zierer, MD, Gerhard Wimmer-Greinecker, MD, Sven Martens, MD, Anton Moritz, MD, and
Mirko Doss, MD
Background: Transcatheter valve implants currently draw their justification for use from reduction of perioper-
ative risk. However, patient age and comorbidities are independent predictors of adverse outcome after aortic
valve replacement, regardless of surgical approach. Therefore, it is unclear whether transapical aortic valve
implantation really improves outcomes in high-risk patients.
Methods:We included a total of 51 high-risk patients with severe aortic valve stenosis. Patients were allocated to
transapical aortic valve implantation (n ¼ 21) or minimally invasive aortic valve replacement via a partial upper
sternotomy (n¼ 30), in a nonrandomized fashion. Patient age, preoperative comorbidities, and perioperative risk,
expressed as logistic EuroSCORE (38%  14% vs 35%  9%), were matched between the 2 groups.
Results: Early morbidity and mortality were comparable between groups, but transapical aortic valve implanta-
tion was associated with shorter operative time (P ¼ .004), ventilation time (P< .001), intensive care unit stay
(P<.001), and hospital stay (P<.001). Thirty-day mortality was 14% (n ¼ 3) in the transcatheter group versus
10% (n¼ 3) in the surgical group. After a mean follow-up of 12 4 months (100% complete), there were a total
of 5 (24%) deaths in the transapical group versus 5 (17%) deaths in the open surgery group. There was 1 intra-
operative death in the transapical group versus none in the surgery group. In the transapical group, there were 2 re-
explorations for bleeding, 2 intraoperative conversions, 1 case of prosthesis migration, and 2 impairments of
coronary arteries. The surgery group included 1 re-exploration, 1 stroke, 1 pacemaker implantation for complete
atrioventricular block, and 3 cases of atrial fibrillation.
Conclusions: Current data suggest a faster postoperative recovery after transapical aortic valve implantation,
with early and late morbidity and mortality comparable with those of minimally invasive aortic valve replacement
via partial upper sternotomy.Classic surgical aortic valve replacement (AVR) with full
sternotomy and cardiopulmonary bypass (CPB) has been
performed for decades and is the established gold standard
in the treatment of severe, symptomatic aortic valve stenosis.
This procedure has been demonstrated to have excellent
functional outcomes with satisfactory long-term survivals
even in patients aged 80 years and older.1-6 Despite all ef-
forts, mortality after routine AVR may be as high as 20%
in patients with significant comorbidities, including left ven-
tricular dysfunction,7 and some have been considered non-
surgical candidates. Thus, there is an ongoing attempt to
evaluate and to define alternative, less invasive treatment op-
tions for these highest risk patients.
The past decade has brought considerable progress in the
development of less invasive approaches to heart valve sur-
gery. Consequently, a variety of partial sternotomies has
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cellent rib cage stability, improved postoperative breathing
mechanics, and reduced pain.8-12 At our center we moved
from a reversed L-shaped partial upper sternotomy (PUS)
into the fourth or fifth right intercostal space to an L-shaped
PUS into the fourth or fifth left intercostal space.13 This
approach became our routine access for aortic valve surgery.
Despite excellent results, the use of CPB, aortic crossclamp-
ing, and cardioplegic arrest are still required.
Most recently, intense interest has been focused toward
the development of a percutaneous catheter–delivered valve
for use in patients with critical aortic stenosis for whom sur-
gical therapy has been rejected.13,14 Selected centers includ-
ing our institution have started to perform the alternative
transapical aortic valve implantation (TAP–AVI) in highest
risk patients with severe symptomatic aortic valve steno-
sis.15-19 Initial results are encouraging, but to date there
are no data available comparing this evolving approach
with an established minimally invasive concept for AVR.
Thus the purpose of the current investigation was to compare
the initial 21 patients who underwent TAP–AVI at our cen-
ter with a matched cohort of 30 patients with minimally in-
vasive AVR via PUS (PUS–AVR).
PATIENTS AND METHODS
The study was approved by the Institutional Review Board of the Hospi-
tal of the Johann Wolfgang Goethe University Frankfurt/Main, Germany,rdiovascular Surgery c Volume 138, Number 5 1067




AVI ¼ aortic valve implantation
AVR ¼ aortic valve replacement
CPB ¼ cardiopulmonary bypass
PUS ¼ partial upper sternotomy
PUS–AVR ¼ minimally invasive aortic valve
replacement via partial upper
sternotomy
TAP–AVI ¼ transapical aortic valve implantation
(implant)
and informed consent and permission for the release of information were
obtained from each patient. For the purpose of this investigation, we first re-
viewed our computerized database of the initial 21 patients who underwent
TAP–AVI between January 2006 and April 2007. We then matched these
21 patients 1:1 with patients who underwent L-shaped PUS–AVR with re-
spect to preoperative variables that are known to affect perioperative and
postoperative outcomes after AVR (Table 1). The resulting 30 PUS–AVR
patients were operated on in 2006 for isolated aortic valve stenosis and rep-
resented the 16% of the total PUS–AVR patients from this time interval
with the highest perioperative risk. Patients included in this study typically
qualified for either approach, and the final decision was mainly based on the
patient’s preference. For operative survivors, mean late follow-up for reop-
eration or death was 12  4 months and was 100% complete. Induction of
anesthesia was performed in a standard fashion in both groups. Propofol in-
fusion was used to maintain anesthesia during postoperative ventilation to
promote early extubation. The current study represents an intent-to-treat
analysis.
TAP–AVI
High-risk patients with severe symptomatic aortic stenosis and an aortic
valve orifice area of 0.8 cm2 or less were selected for TAP–AVI. High risk
was defined by a logistic EuroSCORE predicted risk for mortality of greater
than 20%.18 Additional inclusion criteria for TAP–AVI were an age of 75
years or more, echocardiographically measured aortic annulus diameter of
24 mm or less, as well as symmetrically distributed calcification of the ste-
notic native aortic valve cusps. All operations were performed in a specially
equipped angiography suite that fulfills the standards of a hybrid operating
room. The Cribier–Edwards prosthesis (Cribier–Edwards; Edwards Life-
sciences, Irvine, Calif), which is a pericardial xenograft mounted on a stain-
less steel stent available in two sizes (23 and 26 mm), was used.15,18,20,21
Patients were placed in a supine position. The femoral vessels were exposed,
either for cannulation for CPB or to place a venous and an arterial guidewire
(off-pump procedure) for safety reasons to be prepared for fast cannulation.
Technical details of TAP–AVI have been previously described in de-
tail.15,18,19 In brief, a limited anterolateral incision (5–7 cm), in the fifth in-
tercostal space, was used to access the apex of the heart. A bipolar epicardial
pacing wire was placed and tested. Two U-shaped stitches with Teflon felt
pledgets using 3-0 Prolene polypropylene (Ethicon, Inc, Somerville, NJ)
were placed in the apex of the left ventricle. They served as a purse string
for linear closure of the left ventricle at the end of the procedure. Fluoros-
copy and transesophageal echocardiography were used to guide the catheter
across the native valve and to direct deployment of the stent at the level of
the annulus. During valve deployment, the heart was unloaded with CPB or
with rapid ventricular pacing. Valve function was immediately assessed by
angiographic and echocardiographic visualization. The transapical sheath
was removed and the apex securely closed with the purse-string sutures.
CPBwasweaned (n¼ 11), if necessary, and all cannulas removed. The peri-
cardium was partially closed over the apex and a left lateral chest tube was1068 The Journal of Thoracic and Cardiovascular Sinserted. The incision was closed in a standard fashion. Patient demograph-
ics are summarized in Table 1.
L-Shaped PUS–AVR
The procedure was performed in a routine operating room. Patients were
placed in a supine position. A limited median skin incision (7–9 cm) was
made from just beneath the sternal angle to the fourth intercostal space.
The soft tissue was dissected and a flap was raised to allow access to the ster-
nal notch. The sternumwas opened from the sternal angle to the fourth or fifth
intercostal space. The sternal incision was ‘‘L’d’’ into the left fourth or fifth
intercostal space. Care was taken not to damage the left internal thoracic ar-
tery. Cannulas for CPBwere placed directly into the ascending aorta and right
atrium after the pericardium was opened; the cannulas were tacked to the
drapes under tension with stay sutures. In our experience, this maneuver el-
evated the heart anteriorly and afforded good exposure of the aorta and right
atrium. The field was floodedwith carbon dioxide at 2 L/min to aid resorption
of gas bubbles from the bloodstream. Cardioplegic solution was delivered
only antegradely through an aortic root cannula and after aortotomy by selec-
tive coronary intubation. All subsequent steps of the procedure equaled those
of routine AVR. Perimount–Edwards stented bioprostheses (Edwards Life-
sciences) with a mean size of 22.7  1.6 mm were used in all patients.
Statistical Evaluation
Categorical variables are expressed as percentages and continuous vari-
ables are expressed as mean  standard deviation. All statistical analyses
were performed with SigmaStat 2.03 software (SPSS, Inc, Chicago, Ill).
Comparison of categorical variables was performed with c2 or Fisher’s ex-




In the TAP–AVI group, all valves were successfully
deployed at the target. In 1 patient valve embolization into
the aortic arch occurred during a second inflation of the bal-
loon owing to a severe paravalvular leakage. On control
echocardiography, all other valves showed good hemody-
namic function. Repeat valve dilatation was performed
because of uneven stent expansion leading to moderate or
severe paravalvular leak in 5 (24%) patients. Three (14%)
patients retained mild (first-degree) aortic insufficiency
owing to paravalvular leakages. In 2 patients, conversion
to open surgery was necessary, once in the patient with valve
embolization and again in a patient with a porcelain aorta in
whom a type A dissection developed after balloon dilatation.
Two patients in the transapical group required stent angio-
plasty inasmuch as the left main stem was partially
obstructed by the native valve. In the PUS–AVR group,
all valves showed good hemodynamic function without rel-
evant paravalvular leakage. None of the patients required
conversion to full sternotomy.
Operative time accounted for 154  33 minutes in the
TAP–AVI group versus 208  28 minutes (P ¼ .004) in
the PUS–AVR group. In 15 (71%) patients, TAP–AVI
was performed after cannulation of the femoral vessels.
Nine (43%) of them were actually supported with the
pump for 11  3 minutes to unload the heart during valve
deployment. Two other patients were supported with theurgery c November 2009
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omy. In these 2 patients, crossclamp time was 58  4 min-
utes. The last 10 patients received off-pump TAP–AVI
with only a femoral venous and arterial wire in place. CPB
and aortic crossclamp times in the PUS–AVR group ac-
counted for 113 15 and 71 7 minutes, respectively. Op-
erative outcomes are summarized in Table 2.
Hospital Course
TAP–AVI was associated with shorter ventilation time
(P< .1), intensive care unit stay (P< .001), and hospital
stay (P< .001) than PUS–AVR (Table 3). Two (10%)
patients underwent re-exploration for bleeding versus 1
(3%) in the surgical group. In the PUS–AVR group, there
was 1 (3%) stroke, 1 (3%) pacemaker implantation for
complete atrioventricular block, 3 (10%) cases of atrial
fibrillation, and 3 (10%) cases necessitating postoperative
hemodialysis. None of these morbidities was encountered
in TAP–AVI patients.
Thirty-day mortality was 14% (n¼ 3) in the transcatheter
group (TAP–AVI), including the 1 intraoperative death re-
sulting from dissection of the aortic root. There were another
2 deaths in patients with multisystem organ failure on post-
operative days 3 and 5. The postoperative course in these 2
patients was complicated by leg ischemia after cannulation
of the femoral vessels in 1 patient and development of
a Leriche syndrome in the second patient. Postmortem
TABLE 1. Demographic characteristics of study population
TAP–AVI PUS–AVR P value
No. of patients 21 30 NA
Age (y) 85  6 82  4 NS
Male gender 6 (29%) 11 (37%) NS
Ejection fraction<30% 5 (24%) 6 (20%) NS
Respiratory dysfunction/COPD* 7 (33%) 10 (33%) NS
Diabetes mellitus 6 (29%) 7 (23%) NS
Renal insufficiency 4 (19%) 3 (10%) NS
Coronary artery diseasey 9 (43%) 11 (37%) NS
Presence of mitral incompetence 
second degreez
4 (19%) 6 (20%) NS
Peripheral vascular disease 4 (19%) 7 (23%) NS
Porcelain aorta 3 (14%) 0 NS
NYHA class 3.4  0.4 3.2  0.2 NS
Previous cardiac surgery 3 (14%) 0 NS
Previous stroke 3 (14%) 1(5%) NS
Pulmonary hypertension 6 (29%) 7 (23%) NS
Arrhythmia 6 (29%) 8 (27%) NS
EuroSCORE predicted risk
for mortalityx
38  14% 35  9% NS
n (%) is listed for categorical variables; mean 1 standard deviation for normally dis-
tributed continuous variables. TAP–AVI, Transapical aortic valve implantation; PUS–
AVR, minimally invasive aortic valve replacement via partial upper sternotomy;
COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association;
NS, not significant. *Forced expiratory volume in the first second<1 L; ydiffuse cor-
onary artery disease without any indication for surgical treatment or status-post percu-
taneous transluminal coronary angioplasty; zno indication for concomitant surgical
valve repair; xaccording to logistic EuroSCORE calculations.The Journal of Thoracic and Caassessment in both patients confirmed good prosthetic valve
position and function, as well as patent coronary ostia. In
the PUS–AVR group, 30-day mortality was 10% (n ¼ 3).
One patient died of multisystem organ failure in low-output
syndrome on postoperative day 4, another died of left ven-
tricular failure on postoperative day 6, and the third patient
died of pneumonia after a prolonged stay in the intensive
care unit on postoperative day 21.
One-Year Follow-up
After a mean follow-up of 12 4 months, there were a to-
tal of 5 (24%) deaths in the transapical (TAP–AVI) group
versus 5 (17%) deaths (17%) in the surgery (PUS–AVR)
group (Table 4). In the TAP–AVI group, severe pulmonary
arterial hypertension refractory to maximum medical ther-
apy led to right heart failure with subsequent death 6 months
postoperatively in 1 patient; the other late death was caused
by pneumonia 8 months after intervention. Similarly, there
were 2 late deaths during follow-up in the surgical group,







Operative time (min) 154  33 208  28 .004
CPB time (min) * 113  15 NA
Crossclamp time (min) y 71  7 NA
Type A dissection 1 (5%) 0 NS
Prosthesis migration 1 (5%) 0 NS
Coronary obstruction 2 (10%) 0 NS
Conversion to median sternotomy 2 (10%) 0 NS
Intraoperative death 1 (5%) 0 NS
n (%) is listed for categorical variables; mean 1 standard deviation for normally dis-
tributed continuous variables. TAP–AVI, Transapical aortic valve implantation; PUS–
AVR,minimally invasive aortic valve replacement via partial upper sternotomy; CPB,
cardiopulmonary bypass; NA, not applicable; NS, not significant. *Nine patients were
taken on pump via femoro–femoral cannulation for 11 3 minutes to unload the heart
during valve deployment; 2 patients were taken on pump for 78 7 minutes after con-
version to median sternotomy; ycrossclamp time was 58 4 minutes for the 2 patients
with conversion to median sternotomy.







Ventilation time (h) 6  2 18  3 <.001
ICU stay (d) 1.0  0.4 3.2  1.9 <.001
Hospital stay (d) 5.0  0.9 12  3.4 <.001
Re-exploration 2 (10%) 1 (3%) NS
Complete atrioventricular block 0 1 (3%) NS
Pacemaker implantation 0 1 (3%) NS
Stroke 0 1 (3%) NS
Atrial fibrillation 0 3 (10%) NS
Dialysis 0 3 (10%) NS
Thirty-day mortality 3 (14%) 3 (10%) NS
n (%) is listed for categorical variables; mean 1 standard deviation for normally dis-
tributed continuous variables. TAP–AVI, Transapical aortic valve implantation; PUS–
AVR, minimally invasive aortic valve replacement via partial upper sternotomy; ICU,
intensive care unit; NS, not significant.rdiovascular Surgery c Volume 138, Number 5 1069
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eratively and 1 case of sudden death owing to a ruptured
abdominal aortic aneurysm 11 months after the operation.
There was 1 reoperation in each group.
DISCUSSION
With the recent onset of TAP–AVI in selected centers
including our institution, the invasiveness of surgical
intervention for aortic stenosis has been further reduced by
eliminating the need for CPB, aortic crossclamping, and car-
dioplegic arrest, allowing for a true off-pump procedure
without sternotomy.17-19 Thus TAP–AVIs currently draw
their justification for use from a potential reduction of peri-
operative risk, which intuitively makes sense. However, to
date no data are available comparing this evolving approach
with an established minimally invasive surgical procedure
for AVR. Therefore, it remains unclear whether TAP–AVI
really improves outcomes in high-risk patients.
In comparing operative morbidity in the present study, we
have to keep inmind that TAP–AVI is an emerging approach
with limited worldwide experience. Despite the fact that all
valves were successfully deployed at the target, we faced
some initial technical difficulties early in the series. Owing
to the natural learning curve associated with a new approach,
there were two conversions to open surgery with one causing
the only intraoperative death within this series, and 2 patients
required stent angioplasty inasmuch as the left main stem
was partially obstructed by the native valve. This may
seem a potential disadvantage when compared with the op-
erative outcomes with PUS–AVR. However, widely feared
complications after AVR such as stroke, complete atrioven-
tricular block, and postoperative arrhythmias occurred at
a low incidence within the PUS–AVR group, but were ab-
sent after TAP–AVI. At the same time, current data support
the assumption that reduction of surgical trauma should lead
to a faster postoperative recovery after TAP–AVI because
ventilation time, intensive care unit stay, and hospital stay
were significantly reduced (P< .0001 vs PUS–AVR). Sur-
prisingly, despite the high incidence of renal insufficiency
within this series, the additional burden of 78  41 mL con-
trast given during the procedure did not necessitate postop-







Aortic valve orifice area (cm2) 1.5  0.8 1.7  0.5 NS
Mean transaortic valve
gradient (mm Hg)
9.6  3.7 7.3  3.7 NS
Endocarditis 0 1 (3%) NS
Reoperation 1 (5%) 1 (3%) NS
Overall mortality at 1 year’s follow-up 5 (24%) 5 (17%) NS
n (%) is listed for categorical variables. TAP–AVI, Transapical aortic valve implanta-
tion; PUS–AVR,minimally invasive aortic valve replacement via partial upper sternot-
omy; NS, not significant.1070 The Journal of Thoracic and Cardiovascular Suerative hemodialysis in the TAP–AVI group. In contrast,
the negative impact of CPB on postoperative renal function
was well accepted,22 and 10% of patients actually required
postoperative dialysis after PUS–AVR.
Thirty-day mortality was comparable between the groups,
with 14% in the transapical group and 10% in the surgical
group. Preoperative comorbidities such as peripheral
vascular disease or concomitant coronary artery disease
with reduced left ventricular function complicated the post-
operative course and eventually contributed to early mortal-
ity. According to these preliminary data, there is no survival
advantage with TAP–AVI. On the other hand, one may ar-
gue that an evolving surgical concept is initially judged by
the ability to keep up with the established approach without
compromising survival. Also, with gained experience in the
later half of the TAP–AVI series, we observed a steep learn-
ing curve, particularly with regard to the hemodynamic man-
agement before valve deployment. None of the last 10
patients without femoro–femoral cannulation required sec-
ondary conversion to an on-pump procedure. Severe hypo-
tension and subsequent subendocardial ischemia were
reliably avoided by raising systolic blood pressure to 120
to 140 mm Hg with low-dose norepinephrine before rapid
ventricular pacing during valve deployment. Obviously,
30-day mortality in both groups was far below the predicted
perioperative risk of mortality according to logistic Euro-
SCORE calculations. Such an observation raises the ques-
tion of the reliability of such a risk stratification model.
In patients undergoing heart valve procedures, the Euro-
SCORE model has been shown to be predictive of early
mortality,23 postoperative complications,24 prolonged
length of stay,24 and long-term mortality.25 The use of the
EuroSCORE in predicting operative mortality for high-
risk patients undergoing isolated AVR has yet to be
validated. Although the logistic EuroSCORE model has
been shown to be a better predictor of mortality than the
additive EuroSCORE in high-risk populations,26,27 several
studies have found that the logistic EuroSCORE model
may overestimate the mortality of such patients undergoing
valve procedures.28,29 This is particularly true for patients
aged 80 years and older.30 In contrast, the logistic Euro-
SCORE may underestimate the actual risk of mortality in
patients younger than 80 years. The reason is that various
preoperative comorbidities, including coronary artery
disease, mitral valve incompetence, hepatic disease,
malignancies, cardiovascular risk factors (smoking history,
hypertension), presence of a porcelain aorta, or radiation
of the chest, are not necessarily reflected.18 In fact, we
also believe that in the absence of a uniformly accepted
and validated risk stratification model, we had to use the
EuroSCORE estimate to comply with data presented in
recent clinical series.18,19
At 1 year’s follow-up, the comparable early morbidity and
mortality between TAP–AVI and PUS–AVR werergery c November 2009
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for a 24% mortality rate in the transapical approach versus
17% in the open surgery group.
Potential Limitation
Although our study was not randomized, we matched pa-
tients according to variables known to affect morbidity and
mortality after AVR. Regarding the comparability between
the 2 groups, it also seems important to mention that 6 pa-
tients from the surgical group were initially considered for
TAP–AVI, but eventually underwent PUS–AVR because
of an aortic annulus diameter larger than 25 mm. Another
limitation of our study is its retrospective nature. The study
was not a randomized trial, and some of the observed differ-
ences may thus be attributable to bias or unmeasured factors.
Furthermore, we are comparing a new procedure with an es-
tablished approach. Although this may underestimate the
true benefits of TAP–AVI once the initial learning curve
has been overcome, we believe that we have to share our
early experiences with other centers that are beginning to
pursuit this evolving approach worldwide. This way, sur-
geons will know what clinical results and problems they
may initially face with TAP–AVI as compared with their es-
tablished practice of AVR. Besides, even with growing in-
ternational experience, the initial learning curve of an
individual center cannot be completely eliminated.
In summary, current data suggest a faster postoperative re-
covery after TAP–AVI with early and late morbidity and
mortality comparable with those of PUS–AVR.
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Discussion
Dr Eric Roselli (Cleveland, Ohio). I am also a co-investigator
for the percutaneous valve trial.
Congratulations on a commendable early experience with this
new transapical technology. For now, I believe the real advantage
of this approach is that it offers the ability to provide nonoperative
candidates a viable treatment option for symptomatic and fatal dis-
ease. Although the EuroSCOREs were similar, this scoring system,
like others, has been criticized for the inability to capture lessrdiovascular Surgery c Volume 138, Number 5 1071
Acquired Cardiovascular Disease Zierer et al
A
C
Dquantifiable factors that make a patient high risk. Furthermore, you
could not have matched patients for technical expertise during that
initial learning curve phase, although you did a nice job of address-
ing that point. Were any of these 21 patients deemed to be in inop-
erable condition and therefore part of a different population from
the matched cohort, and were any symptomatic patients with severe
aortic stenosis treated medically during this time period? If so, how
did they do?
Dr Doss. Thank you very much for your comments. Of course,
matching these patients is difficult. As you have pointed out, the
transapical group included patients who were in somewhat inoper-
able condition. We had patients with porcelain aortas and we had
redo patients, which we did not have in the surgical group. There-
fore, this was a very sick and very challenging operative group of
patients.
Dr Roselli.Did you evaluate any medically treated patients dur-
ing this time period?
Dr Doss. No, we did not have a medical treatment arm. We did
have patients who were on the waiting list and died while waiting
for surgery, but we did not have a specific medical arm for these
patients.
Dr Roselli. I believe that this technology will become another
important tool in our armamentarium, especially for high-risk pa-
tients, but I worry that the attraction of this less invasive approach
may cloud our judgment in providing patients with a durable oper-
ation, especially if the delivery systems improve access and accu-
racy in deployment. You had 5 patients, I believe, who required
repeat balloon valvuloplasty and 1 patient in each of the 2 groups
who required late reoperation. Can you provide any further fol-
low?up data on echocardiographic evidence of aortic insufficiency
and describe how you monitored these patients afterward?
Dr Doss. As I said before, 4 patients had paravalvular leakages;
the leakages were not significant. We followed them up according
to the protocol, which was after 30 days, after 6 months, and after 1
year, and thereafter we monitored them yearly. Of those patients
who had paravalvular leakages, none of the patients actually
went on to have a hemolysis, and none of the patients required a re-
operation for hemodynamic compromise. Also, none of these in-
competencies increased the grading. Therefore, it was something1072 The Journal of Thoracic and Cardiovascular Sthat we also had to learn—that leaving paravalvular leakages that
are not significant can actually be tolerated by the patient. A sur-
geon would try to reoperate on these patients as soon as possible,
but in these procedures, these patients tended to do well even
though these paravalvular leakages were not treated.
Dr Lars Svensson (Cleveland, Ohio). It is interesting to see how
the group of high-risk patients has increased in Europe, and that
certainly has been our impression with our patients. We looked at
our first 92 patients who were referred for percutaneous valves: es-
sentially 20% underwent open surgery with no deaths, 20% re-
ceived percutaneous valves and did pretty well, and 20% just had
balloon valvuloplasty; another 40% died before the procedure, re-
fused, or were not suitable for any type of procedure.
Are you doing a lot of balloon valvuloplasty bridging for later
procedures?
Dr Doss. Actually, we did that in only 2 patients. Those were
patients with very bad left ventricular function, less than 20%.
Bridging was done in an attempt to let them improve and then be
available for a later transapical procedure.
Dr William Northrup III (Kennesaw, Ga). I have one simple
question in the context of Craig Miller’s provocative presidential
address. How many of your patients eventually ended up going
back to their own ZIP codes?
Dr Doss. I did not quite get the phrase.
Dr Svensson. How many of those patients went back to normal
reasonable lifestyles in their home village?
DrDoss. The big advantage of the transapical procedure is that if
you treat these very sick patients, you actually see that they do have
a much improved and better course in the hospital. The second
patient on whom we performed the transapical procedure was
a 92-year-old man with coronary artery disease. We stented his
coronary arteries, 1 month later we did the procedure, and the pa-
tient returned to the hospital with his wife 1 year later. He was liv-
ing at home and taking care of himself. Of course, he will not live
another 10 years, but the improvement in his quality of life was dra-
matic. It is dramatic with this type of procedure. The transapical
procedure is worth doing, not necessarily to improve their survival,
but definitely to improve their quality of life during the time that
they have left.urgery c November 2009
